Prospective, Non-Interventional Study of K-ras Status Switch in K-ras Native Patients With Metastatic Colorectal Tumors Treated With FOLFIRI-Cetuximab as First-line Treatment
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Mar 2017
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms BEAMING
- 31 Aug 2018 Biomarkers information updated
- 16 Mar 2015 Planned primary completion date changed to 1 Apr 2015 as reported by ClinicalTrial.gov record.
- 16 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov record.